guanidinium

Guanidine hydrochloride (Aminoformamidine Hydrochloride) is a strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant.

GPMA is a cationic copolymerization agent used for creating polymer complexes to facilitate the delivery of plasmid DNA in vitro.

Biguanidinium-porphyrin is a phototoxic agent with anti-proliferative activity.

Biguanidinium-porphyrin free TFA is a mitochondrial-targeting photosensitiser exhibiting low dark toxicity towards human hepatocellular carcinoma HEp2 cells (IC50=8.2 mM, 1 J/cm²).

Aminoguanidine hydrochloride (Hydrazinecarboximidamide) is a diamine oxidase and NO synthase inhibitor, used in the treatment of diabetic nephropathy.

Aminoguanidine-13C,15N4 (Pimagedine-13C,15N4) is a carbon-13 and nitrogen-15 labeled form of Aminoguanidine. Aminoguanidine (Pimagedine hydrochloride) functions as an inhibitor of diamine oxidase and nitric oxide synthase. It exhibits dose-dependent inhibitory effects on apoptosis induced by adriamycin and possesses antioxidant properties. This compound is utilized in studies related to diabetic nephropathy.

Fmoc-N-Me-Arg(Pbf)-OH, an amino acid derivative, features a guanidinium protecting group attached to the arginine side chain. This compound is utilized in crafting NTS1 ligands derived from neurotensin for PET imaging applications.

CBB1007 trihydrochloride is a cell-permeable amidino-guanidinium compound that acts as a potent, reversible and substrate competitive LSD1 selective inhibitor (IC50 = 5.27 μM for hLSD1). IC50 Value: 5.27 uM Target: hLSD1 CBB1007 efficiently can block LSD1-mediated demethylation of H3K4Me2 and H3K4Me (IC50 ≤ 5 μM) with no effect on H3K4Me3 and H3K9Me2, and LSD2 and JARID1A activities. Increases H3K4Me2 and H3K4Me contents (IC50 ≤ 5 μM), and causes activation of epigenetically suppressed CHRM4/M4-ArchR and SCN3A genes in F9 cells (IC50 ≤ 3.74 μM). CBB1007 was Shown to preferentially arrest the growth of pluripotent tumors with minimal effect on non-pluripotent cancer or normal somatic cells (IC50 ≥ 100 μM).

CBB1007 HCl is a cell-permeable amidino-guanidinium compound identified as a potent, reversible, and substrate-competitive inhibitor of LSD1 (IC50 = 5.27 μM for hLSD1). It effectively inhibits LSD1-mediated demethylation of H3K4Me2 and H3K4Me (IC50 ≤ 5 μM), without affecting H3K4Me3 and H3K9Me2 demethylation, nor the activities of LSD2 and JARID1A. Moreover, CBB1007 increases the levels of H3K4Me2 and H3K4Me (IC50 ≤ 5 μM) and activates epigenetically suppressed genes CHRM4/M4-ArchR and SCN3A in F9 cells (IC50 ≤ 3.74 μM). It preferentially inhibits the growth of pluripotent tumors with minimal impact on non-pluripotent cancer or normal somatic cells (IC50 ≥ 100 μM).

Guanidine-D5 hydrochloride is the deuterated form of Guanidine hydrochloride. Guanidine hydrochloride (T0415) (Guanidinium chloride) acts as a potent chaotropic agent and is a strong protein denaturant.